Hospital

For adolescents and young adults affected by HIV, Google yielded higher quality information on pre-exposure prophylaxis more frequently compared to other search engines.

Quitting treatment may significantly improve severe hypertension in patients with hepatocellular carcinoma.

Managing cost savings can soften the blow of direct and indirect remuneration fee reform that will impact pharmacists during the first half of 2024.

Christina M. Madison, PharmD, FCCP, AAHIVP, sat down with Lydia Bailey, PharmD, BCACP, pharmacy operations manager at St. Vincent De Paul Charitable Pharmacy

These data support a paradigm shift in the treatment of locally advanced rectal cancer.

Despite the surge in new diabetes cases, the treatment options in in children remain limited.

For many patients with C diff, the experience of medical gaslighting is a common one because many health care providers lack education and familiarity with the disease.

Idiopathic intracranial hypertension was previously considered a rare condition, however, its prevalence is increasing in parallel with obesity in patient populations.

Investigators said pre-exposure prophylaxis rollout is efficient in settings with high HIV incidence, but not in settings with low HIV incidence.

Specialty pharmacists can have more contact with patients than providers.

Generic ketamine could cost as little as $5, which is significantly lower than the $800 per dose for the currently available S-ketamine nasal spray.

Due to the assessment of computerized tomography with criteria from 1999, the role of radiotherapy in patients with diffuse large B-cell lymphoma with bulky or extranodal disease remains undefined.

Patients with perinatally-acquired HIV reported low emotional, instrumental, and friendship support at 37%, 32%, and 36%, respectively.

The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.

Participants were able to stop treatment after achieving amyloid plaque clearance and experience lasting results.

Therapeutic drug monitoring is a growing and vital area for pharmacists to become involved in to increase patient success with inflammatory bowel disease remission.

Though the overall significance of the results were low, vitamin D was found to be especially useful in lowering the prevalence of myocardial infarction in older adults.

Pharmacist-led discharge stewardship initiatives have shown promising results.

A significant proportion of patients had negative hepatitis B surface antibody titers, indicating a need for vaccination to ensure protection for patients undergoing hemodialysis.

The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.

FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.

High doses of intravenous immunoglobulin can result in expensive medical treatments for the families of children with immune thrombocytopenia.

Every pharmacist can make a difference in patients’ lives by taking the time to understand and fulfill the community’s social and cultural needs.

Chemotherapy may increase inflammatory biomarkers that can impact the diversity of the gut microbiome, leading to serious anthropomorphic changes among women treated for early-stage breast cancer.

A panel at the Advanced Topics for Oncology Pharmacy Professionals Summit discusses strategies to address patients’ fears and distrust of the medical and scientific community.

Effective implementation of the Inflation Reduction Act may allow legislators to shift their focus toward controversial pharmacy benefit manager practices, according to a panel discussion during the ATOPP Summit.

Zanubrutinib combined with obinutuzumab was previously granted both Fast Track and Orphan drug designations for patients with relapsed or refractory follicular lymphoma.

Despite a slew of barriers with patient management, pharmacists have the training and resources to advocate for better patient care and help patients with hematologic myeloproliferative neoplasms advocate for themselves.